+Follow
梦想1
No personal profile
40
Follow
1
Followers
0
Topic
0
Badge
Posts
Hot
梦想1
2023-01-19
$Faraday Future(FFIE)$
梦想1
2021-06-23
，
Guichuang Tongqiao-B begins its IPO today, with an entry fee of approximately HK$21,565.15 per lot.
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3533893606092940","uuid":"3533893606092940","gmtCreate":1570799584136,"gmtModify":1623980210117,"name":"梦想1","pinyin":"mx1mengxiang1","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/a6080bf89a981cc882d2bb524a614432","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":40,"tweetSize":8,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-4","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Tiger Star","description":"Join the tiger community for 2000 days","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.13%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.56%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":626649424,"gmtCreate":1674139521369,"gmtModify":1676538926189,"author":{"id":"3533893606092940","authorId":"3533893606092940","name":"梦想1","avatar":"https://static.tigerbbs.com/a6080bf89a981cc882d2bb524a614432","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3533893606092940","authorIdStr":"3533893606092940"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$ </a>","listText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$ </a>","text":"$Faraday Future(FFIE)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/626649424","isVote":1,"tweetType":1,"viewCount":3877,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121693498,"gmtCreate":1624460687414,"gmtModify":1703837517034,"author":{"id":"3533893606092940","authorId":"3533893606092940","name":"梦想1","avatar":"https://static.tigerbbs.com/a6080bf89a981cc882d2bb524a614432","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3533893606092940","authorIdStr":"3533893606092940"},"themes":[],"title":"","htmlText":"，","listText":"，","text":"，","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/121693498","repostId":"1175917752","repostType":4,"repost":{"id":"1175917752","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624324803,"share":"https://ttm.financial/m/news/1175917752?lang=en_US&edition=fundamental","pubTime":"2021-06-22 09:20","market":"hk","language":"zh","title":"Guichuang Tongqiao-B begins its IPO today, with an entry fee of approximately HK$21,565.15 per lot.","url":"https://stock-news.laohu8.com/highlight/detail?id=1175917752","media":"老虎资讯综合","summary":"6月22日讯，归创通桥-B港交所公告，公司于2021年6月22日-25日招股，拟全球发售6000万股H股，香港公开发售占10%，国际发售占90%，另有15%超额配股权。每股39.8-42.7港元，每手","content":"<p>June 22nd news,<a href=\"https://laohu8.com/S/02190\">Guichuang Tongqiao-B</a>The Hong Kong Stock Exchange announced that the company will conduct an IPO from June 22 to 25, 2021, with a proposed global offering of 60 million H shares, of which 10% will be offered in Hong Kong, 90% will be offered internationally, and there will be an over-allotment option of 15%. The shares are expected to be listed on the Main Board of the Stock Exchange on July 5, 2021, at HK$39.8-42.7 per share, with 500 shares per lot. Morgan Stanley and CITIC Securities are the joint sponsors.</p><p><b>Tiger Trade will open for subscription at 11:30.</b><a href=\"https://www-web.itiger.com/mi/ipo/index/hk/listing\" target=\"_blank\"><b>Subscription portal</b></a><b>】</b></p><p><img src=\"https://static.tigerbbs.com/5ccb18cb1738a92a6923b389fc572338\" tg-width=\"845\" tg-height=\"754\" referrerpolicy=\"no-referrer\"></p><p><b>Subscription ladder:</b></p><p>Each lot contains 500 shares, with an entry fee of HK$21,565.15.</p><p>The threshold for Group B is 200,000 shares, and the funds required for subscription are approximately HK$8,626,057.58.</p><p><img src=\"https://static.tigerbbs.com/5b4abbd517a0577df2659dfacaca93e3\" tg-width=\"869\" tg-height=\"653\" referrerpolicy=\"no-referrer\"></p><p>In terms of its comprehensive product portfolio, the company is a leader in China's neurological and peripheral vascular interventional medical device market. As a comprehensive medical device company supported by independent R&D and manufacturing capabilities, proprietary technology platforms, and proven commercialization capabilities, and led by an experienced management team, the company provides medical devices for the treatment and management of neurological and peripheral vascular diseases to doctors and patients in China and overseas. The company's current treatment areas include acute ischemic stroke (AIS), intracranial aneurysms, carotid artery stenosis, peripheral arterial and venous diseases, and dialysis-related diseases.</p><p>According to Frost & Sullivan, the company has 22 approved products and product candidates. Among domestic players in China, the company has the most comprehensive portfolio of peripheral vascular interventional products, covering a full range of arterial and venous products such as stents, balloons, catheters and filters. In addition, the company's product portfolio also includes two vascular closure device candidates, making the company the first medical device company in China to develop a vascular closure device candidate. Since its establishment in 2012, the company has systematically and comprehensively developed 45 products and product candidate portfolios, covering the neurological and peripheral vascular device market and the vascular closure device market, all of which are characterized by serious insufficient penetration and rapid development. The company's two core products are the Jiaolong intracranial thrombectomy stent and the UltrafreeTM drug-eluting PTA balloon dilatation catheter (Ultrafree DCB). These two core products have been commercialized in China, and the company is conducting further research and development on these two core products.</p><p>Financial data shows that in 2019 and 2020, the company achieved revenue of RMB 4.917 million and RMB 27.631 million, respectively; The net losses were approximately RMB 66.647 million and RMB 100 million, respectively. The majority of the operating losses were attributable to costs incurred by the Company in selling and distribution expenses, research and development expenses and administrative expenses related to going concern.</p><p><img src=\"https://static.tigerbbs.com/7ae57878256177f384fa6f1f7336dc10\" tg-width=\"667\" tg-height=\"810\" referrerpolicy=\"no-referrer\"></p><p>In addition, the company will continue to incur huge losses in 2021 as it continues to invest heavily in research and development activities to expand the development of its product candidates and seek regulatory approval for them.</p><p>The announcement stated that the company has entered into cornerstone investment agreements with 12 cornerstone investors, who have agreed, subject to certain conditions, to subscribe for a certain number of offer shares at the offer price, which can be purchased for a total amount of US$145 million.</p><p>To the best of the Company's knowledge, except that AIHC, Cormorant, Hudson Bay, Lake Bleu Prime and Octagon are all existing shareholders of the Company or their close associates, each of the Cornerstone Investors is an independent third party and is not a related party of the Company. Among them, Gaoling Fund, LP, YHG Investment, LP, and Fidelity International Lake Bleu Prime, Boyu Capital Opportunity Master Fund, AIHC Master Fund, Hudson Bay and Snow Lake Fund The subscription amounts were $30 million, $20 million, $20 million, $16 million, $16 million, $10 million, and $10 million, respectively.</p><p><img src=\"https://static.tigerbbs.com/9817ed27c529206fe64fd47ee9d9ddd2\" tg-width=\"610\" tg-height=\"726\" referrerpolicy=\"no-referrer\"></p><p>Assuming the Over-allotment Option is not exercised and the Offer Price is HK$41.25 per Share, the net proceeds from the Global Offering will be approximately HK$2.314 billion. Approximately 12.5% will be allocated to the continued research, development, production, and commercialization of the Jiaolong intracranial thrombectomy stent; Approximately 24.5% will be allocated to the continued research, development, production, and commercialization of the core product, Ultrafree DCB; Approximately 11.0% will be allocated to the continued research and development, production, and commercialization of the other five major products; Approximately 40.0% will be allocated to the other 38 products and pipelines under development to develop a product portfolio to provide full-line solutions. Approximately 3.0% will be allocated to further upgrading research and development facilities; Approximately 4.0% is allocated for potential strategic acquisitions, investments, licensed introductions, or cooperation; and approximately 5.0% will be used for working capital and general corporate purposes.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Guichuang Tongqiao-B begins its IPO today, with an entry fee of approximately HK$21,565.15 per lot.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGuichuang Tongqiao-B begins its IPO today, with an entry fee of approximately HK$21,565.15 per lot.\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-06-22 09:20</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>June 22nd news,<a href=\"https://laohu8.com/S/02190\">Guichuang Tongqiao-B</a>The Hong Kong Stock Exchange announced that the company will conduct an IPO from June 22 to 25, 2021, with a proposed global offering of 60 million H shares, of which 10% will be offered in Hong Kong, 90% will be offered internationally, and there will be an over-allotment option of 15%. The shares are expected to be listed on the Main Board of the Stock Exchange on July 5, 2021, at HK$39.8-42.7 per share, with 500 shares per lot. Morgan Stanley and CITIC Securities are the joint sponsors.</p><p><b>Tiger Trade will open for subscription at 11:30.</b><a href=\"https://www-web.itiger.com/mi/ipo/index/hk/listing\" target=\"_blank\"><b>Subscription portal</b></a><b>】</b></p><p><img src=\"https://static.tigerbbs.com/5ccb18cb1738a92a6923b389fc572338\" tg-width=\"845\" tg-height=\"754\" referrerpolicy=\"no-referrer\"></p><p><b>Subscription ladder:</b></p><p>Each lot contains 500 shares, with an entry fee of HK$21,565.15.</p><p>The threshold for Group B is 200,000 shares, and the funds required for subscription are approximately HK$8,626,057.58.</p><p><img src=\"https://static.tigerbbs.com/5b4abbd517a0577df2659dfacaca93e3\" tg-width=\"869\" tg-height=\"653\" referrerpolicy=\"no-referrer\"></p><p>In terms of its comprehensive product portfolio, the company is a leader in China's neurological and peripheral vascular interventional medical device market. As a comprehensive medical device company supported by independent R&D and manufacturing capabilities, proprietary technology platforms, and proven commercialization capabilities, and led by an experienced management team, the company provides medical devices for the treatment and management of neurological and peripheral vascular diseases to doctors and patients in China and overseas. The company's current treatment areas include acute ischemic stroke (AIS), intracranial aneurysms, carotid artery stenosis, peripheral arterial and venous diseases, and dialysis-related diseases.</p><p>According to Frost & Sullivan, the company has 22 approved products and product candidates. Among domestic players in China, the company has the most comprehensive portfolio of peripheral vascular interventional products, covering a full range of arterial and venous products such as stents, balloons, catheters and filters. In addition, the company's product portfolio also includes two vascular closure device candidates, making the company the first medical device company in China to develop a vascular closure device candidate. Since its establishment in 2012, the company has systematically and comprehensively developed 45 products and product candidate portfolios, covering the neurological and peripheral vascular device market and the vascular closure device market, all of which are characterized by serious insufficient penetration and rapid development. The company's two core products are the Jiaolong intracranial thrombectomy stent and the UltrafreeTM drug-eluting PTA balloon dilatation catheter (Ultrafree DCB). These two core products have been commercialized in China, and the company is conducting further research and development on these two core products.</p><p>Financial data shows that in 2019 and 2020, the company achieved revenue of RMB 4.917 million and RMB 27.631 million, respectively; The net losses were approximately RMB 66.647 million and RMB 100 million, respectively. The majority of the operating losses were attributable to costs incurred by the Company in selling and distribution expenses, research and development expenses and administrative expenses related to going concern.</p><p><img src=\"https://static.tigerbbs.com/7ae57878256177f384fa6f1f7336dc10\" tg-width=\"667\" tg-height=\"810\" referrerpolicy=\"no-referrer\"></p><p>In addition, the company will continue to incur huge losses in 2021 as it continues to invest heavily in research and development activities to expand the development of its product candidates and seek regulatory approval for them.</p><p>The announcement stated that the company has entered into cornerstone investment agreements with 12 cornerstone investors, who have agreed, subject to certain conditions, to subscribe for a certain number of offer shares at the offer price, which can be purchased for a total amount of US$145 million.</p><p>To the best of the Company's knowledge, except that AIHC, Cormorant, Hudson Bay, Lake Bleu Prime and Octagon are all existing shareholders of the Company or their close associates, each of the Cornerstone Investors is an independent third party and is not a related party of the Company. Among them, Gaoling Fund, LP, YHG Investment, LP, and Fidelity International Lake Bleu Prime, Boyu Capital Opportunity Master Fund, AIHC Master Fund, Hudson Bay and Snow Lake Fund The subscription amounts were $30 million, $20 million, $20 million, $16 million, $16 million, $10 million, and $10 million, respectively.</p><p><img src=\"https://static.tigerbbs.com/9817ed27c529206fe64fd47ee9d9ddd2\" tg-width=\"610\" tg-height=\"726\" referrerpolicy=\"no-referrer\"></p><p>Assuming the Over-allotment Option is not exercised and the Offer Price is HK$41.25 per Share, the net proceeds from the Global Offering will be approximately HK$2.314 billion. Approximately 12.5% will be allocated to the continued research, development, production, and commercialization of the Jiaolong intracranial thrombectomy stent; Approximately 24.5% will be allocated to the continued research, development, production, and commercialization of the core product, Ultrafree DCB; Approximately 11.0% will be allocated to the continued research and development, production, and commercialization of the other five major products; Approximately 40.0% will be allocated to the other 38 products and pipelines under development to develop a product portfolio to provide full-line solutions. Approximately 3.0% will be allocated to further upgrading research and development facilities; Approximately 4.0% is allocated for potential strategic acquisitions, investments, licensed introductions, or cooperation; and approximately 5.0% will be used for working capital and general corporate purposes.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18","relate_stocks":{"02190":"归创通桥"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1175917752","content_text":"6月22日讯，归创通桥-B港交所公告，公司于2021年6月22日-25日招股，拟全球发售6000万股H股，香港公开发售占10%，国际发售占90%，另有15%超额配股权。每股39.8-42.7港元，每手500股，摩根士丹利及中信证券为联席保荐人，预期股份将于2021年7月5日于联交所主板挂牌上市。\nTiger Trade将于11:30开放申购【申购入口】\n\n申购阶梯：\n每手500股，入场费21565.15港元。\n乙组门槛为20万股，申购所需资金约8626057.58港元。\n\n就公司全面的产品组合而言，公司是中国神经和外周血管介入医疗器械市场的领导者。作为一家以自主研发及制造能力、专有技术平台及经良好往绩记录证实的商业化能力为支撑，并由经验丰富的管理团队带领的综合医疗器械公司，公司为中国及海外的医生和患者提供治疗及应对神经和外周血管疾病的医疗器械。公司目前的治疗领域包括急性缺血性脑卒中(AIS)、颅内动脉瘤、颈动脉狭窄、外周动脉和静脉疾病及透析相关疾病。\n根据弗若斯特沙利文的资料，公司拥有22款获批产品及候选产品，在中国的国内参与者中，公司拥有最全面的外周血管介入产品组合，涵盖支架、球囊、导管和滤器等全系列动脉和静脉产品。此外，公司的产品组合亦包括两款血管闭合装置候选产品，使公司成为国内首家开发出血管闭合装置候选产品的医疗器械公司。自2012年创立以来，公司已系统、全面地开发出45款产品及候选产品组合，涵盖神经及外周血管器械市场及血管闭合装置市场，这些市场都存在渗透率严重不足且发展迅速的特点。公司的两款核心产品是蛟龙颅内取栓支架和UltrafreeTM药物洗脱PTA球囊扩张导管(Ultrafree DCB)，这两款核心产品已在中国实现商业化，且公司正在对这两款核心产品展开进一步研发。\n财务资料显示，于2019年及2020年，实现收入分别为人民币491.7万元及2763.1万元;净亏损分别为约人民币6664.7万元及1亿元。经营亏损的绝大部分是由公司的销售及分销开支、研发开支以及与持续经营相关的行政开支所产生的成本所致。\n\n此外，将于2021年继续产生巨额亏损，原因是公司继续大力投资研发活动，以扩大对候选产品的开发及寻求候选产品的监管批准。\n公告称，公司已与12位基石投资者订立基石投资协议，基石投资者已同意在若干条件的规限下，按发售价认购以总金额1.45亿美元可购买的一定数目的发售股份。\n据公司所深知，除AIHC、Cormorant、Hudson Bay、Lake Bleu Prime及 Octagon均为公司现有股东或彼等的紧密联系人外，各基石投资者均为独立第三方且并非公司的关联人士。其中，Gaoling Fund, L.P.及 YHG Investment, L.P、富达国际、Lake Bleu Prime、Boyu Capital Opportunity Master Fund、AIHC Master Fund 、Hudson Bay及Snow Lake Fund认购额分别为3000万美元、2000万美元、2000万美元、1600万美元、1600万美元、1000万美元及1000万美元。\n\n假设超额配售权未获行使且假设发售价为每股股份41.25港元，全球发售净筹约23.14亿港元。约12.5%将被分配予蛟龙颅内取栓支架的持续研发、生产及商业化;约24.5%将被分配予核心产品Ultrafree DCB的持续研发、生产及商业化; 约11.0%将被分配予其他5款主要产品的持续研发、生产及商业化;约40.0%将被分配予其他38款产品及在研管线，以便开发产品组合以提供全线解决方案。约3.0%将分配予进一步升级研发设施;约4.0%被分配用于潜在战略收购、投资、授权引进或合作;及约5.0%将用于营运资金及一般公司用途。","news_type":1,"symbols_score_info":{"02190":0.9}},"isVote":1,"tweetType":1,"viewCount":4143,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":626649424,"gmtCreate":1674139521369,"gmtModify":1676538926189,"author":{"id":"3533893606092940","authorId":"3533893606092940","name":"梦想1","avatar":"https://static.tigerbbs.com/a6080bf89a981cc882d2bb524a614432","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3533893606092940","idStr":"3533893606092940"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$ </a>","listText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$ </a>","text":"$Faraday Future(FFIE)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/626649424","isVote":1,"tweetType":1,"viewCount":3877,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121693498,"gmtCreate":1624460687414,"gmtModify":1703837517034,"author":{"id":"3533893606092940","authorId":"3533893606092940","name":"梦想1","avatar":"https://static.tigerbbs.com/a6080bf89a981cc882d2bb524a614432","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3533893606092940","idStr":"3533893606092940"},"themes":[],"title":"","htmlText":"，","listText":"，","text":"，","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/121693498","repostId":"1175917752","repostType":4,"repost":{"id":"1175917752","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624324803,"share":"https://ttm.financial/m/news/1175917752?lang=en_US&edition=fundamental","pubTime":"2021-06-22 09:20","market":"hk","language":"zh","title":"Guichuang Tongqiao-B begins its IPO today, with an entry fee of approximately HK$21,565.15 per lot.","url":"https://stock-news.laohu8.com/highlight/detail?id=1175917752","media":"老虎资讯综合","summary":"6月22日讯，归创通桥-B港交所公告，公司于2021年6月22日-25日招股，拟全球发售6000万股H股，香港公开发售占10%，国际发售占90%，另有15%超额配股权。每股39.8-42.7港元，每手","content":"<p>June 22nd news,<a href=\"https://laohu8.com/S/02190\">Guichuang Tongqiao-B</a>The Hong Kong Stock Exchange announced that the company will conduct an IPO from June 22 to 25, 2021, with a proposed global offering of 60 million H shares, of which 10% will be offered in Hong Kong, 90% will be offered internationally, and there will be an over-allotment option of 15%. The shares are expected to be listed on the Main Board of the Stock Exchange on July 5, 2021, at HK$39.8-42.7 per share, with 500 shares per lot. Morgan Stanley and CITIC Securities are the joint sponsors.</p><p><b>Tiger Trade will open for subscription at 11:30.</b><a href=\"https://www-web.itiger.com/mi/ipo/index/hk/listing\" target=\"_blank\"><b>Subscription portal</b></a><b>】</b></p><p><img src=\"https://static.tigerbbs.com/5ccb18cb1738a92a6923b389fc572338\" tg-width=\"845\" tg-height=\"754\" referrerpolicy=\"no-referrer\"></p><p><b>Subscription ladder:</b></p><p>Each lot contains 500 shares, with an entry fee of HK$21,565.15.</p><p>The threshold for Group B is 200,000 shares, and the funds required for subscription are approximately HK$8,626,057.58.</p><p><img src=\"https://static.tigerbbs.com/5b4abbd517a0577df2659dfacaca93e3\" tg-width=\"869\" tg-height=\"653\" referrerpolicy=\"no-referrer\"></p><p>In terms of its comprehensive product portfolio, the company is a leader in China's neurological and peripheral vascular interventional medical device market. As a comprehensive medical device company supported by independent R&D and manufacturing capabilities, proprietary technology platforms, and proven commercialization capabilities, and led by an experienced management team, the company provides medical devices for the treatment and management of neurological and peripheral vascular diseases to doctors and patients in China and overseas. The company's current treatment areas include acute ischemic stroke (AIS), intracranial aneurysms, carotid artery stenosis, peripheral arterial and venous diseases, and dialysis-related diseases.</p><p>According to Frost & Sullivan, the company has 22 approved products and product candidates. Among domestic players in China, the company has the most comprehensive portfolio of peripheral vascular interventional products, covering a full range of arterial and venous products such as stents, balloons, catheters and filters. In addition, the company's product portfolio also includes two vascular closure device candidates, making the company the first medical device company in China to develop a vascular closure device candidate. Since its establishment in 2012, the company has systematically and comprehensively developed 45 products and product candidate portfolios, covering the neurological and peripheral vascular device market and the vascular closure device market, all of which are characterized by serious insufficient penetration and rapid development. The company's two core products are the Jiaolong intracranial thrombectomy stent and the UltrafreeTM drug-eluting PTA balloon dilatation catheter (Ultrafree DCB). These two core products have been commercialized in China, and the company is conducting further research and development on these two core products.</p><p>Financial data shows that in 2019 and 2020, the company achieved revenue of RMB 4.917 million and RMB 27.631 million, respectively; The net losses were approximately RMB 66.647 million and RMB 100 million, respectively. The majority of the operating losses were attributable to costs incurred by the Company in selling and distribution expenses, research and development expenses and administrative expenses related to going concern.</p><p><img src=\"https://static.tigerbbs.com/7ae57878256177f384fa6f1f7336dc10\" tg-width=\"667\" tg-height=\"810\" referrerpolicy=\"no-referrer\"></p><p>In addition, the company will continue to incur huge losses in 2021 as it continues to invest heavily in research and development activities to expand the development of its product candidates and seek regulatory approval for them.</p><p>The announcement stated that the company has entered into cornerstone investment agreements with 12 cornerstone investors, who have agreed, subject to certain conditions, to subscribe for a certain number of offer shares at the offer price, which can be purchased for a total amount of US$145 million.</p><p>To the best of the Company's knowledge, except that AIHC, Cormorant, Hudson Bay, Lake Bleu Prime and Octagon are all existing shareholders of the Company or their close associates, each of the Cornerstone Investors is an independent third party and is not a related party of the Company. Among them, Gaoling Fund, LP, YHG Investment, LP, and Fidelity International Lake Bleu Prime, Boyu Capital Opportunity Master Fund, AIHC Master Fund, Hudson Bay and Snow Lake Fund The subscription amounts were $30 million, $20 million, $20 million, $16 million, $16 million, $10 million, and $10 million, respectively.</p><p><img src=\"https://static.tigerbbs.com/9817ed27c529206fe64fd47ee9d9ddd2\" tg-width=\"610\" tg-height=\"726\" referrerpolicy=\"no-referrer\"></p><p>Assuming the Over-allotment Option is not exercised and the Offer Price is HK$41.25 per Share, the net proceeds from the Global Offering will be approximately HK$2.314 billion. Approximately 12.5% will be allocated to the continued research, development, production, and commercialization of the Jiaolong intracranial thrombectomy stent; Approximately 24.5% will be allocated to the continued research, development, production, and commercialization of the core product, Ultrafree DCB; Approximately 11.0% will be allocated to the continued research and development, production, and commercialization of the other five major products; Approximately 40.0% will be allocated to the other 38 products and pipelines under development to develop a product portfolio to provide full-line solutions. Approximately 3.0% will be allocated to further upgrading research and development facilities; Approximately 4.0% is allocated for potential strategic acquisitions, investments, licensed introductions, or cooperation; and approximately 5.0% will be used for working capital and general corporate purposes.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Guichuang Tongqiao-B begins its IPO today, with an entry fee of approximately HK$21,565.15 per lot.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGuichuang Tongqiao-B begins its IPO today, with an entry fee of approximately HK$21,565.15 per lot.\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-06-22 09:20</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>June 22nd news,<a href=\"https://laohu8.com/S/02190\">Guichuang Tongqiao-B</a>The Hong Kong Stock Exchange announced that the company will conduct an IPO from June 22 to 25, 2021, with a proposed global offering of 60 million H shares, of which 10% will be offered in Hong Kong, 90% will be offered internationally, and there will be an over-allotment option of 15%. The shares are expected to be listed on the Main Board of the Stock Exchange on July 5, 2021, at HK$39.8-42.7 per share, with 500 shares per lot. Morgan Stanley and CITIC Securities are the joint sponsors.</p><p><b>Tiger Trade will open for subscription at 11:30.</b><a href=\"https://www-web.itiger.com/mi/ipo/index/hk/listing\" target=\"_blank\"><b>Subscription portal</b></a><b>】</b></p><p><img src=\"https://static.tigerbbs.com/5ccb18cb1738a92a6923b389fc572338\" tg-width=\"845\" tg-height=\"754\" referrerpolicy=\"no-referrer\"></p><p><b>Subscription ladder:</b></p><p>Each lot contains 500 shares, with an entry fee of HK$21,565.15.</p><p>The threshold for Group B is 200,000 shares, and the funds required for subscription are approximately HK$8,626,057.58.</p><p><img src=\"https://static.tigerbbs.com/5b4abbd517a0577df2659dfacaca93e3\" tg-width=\"869\" tg-height=\"653\" referrerpolicy=\"no-referrer\"></p><p>In terms of its comprehensive product portfolio, the company is a leader in China's neurological and peripheral vascular interventional medical device market. As a comprehensive medical device company supported by independent R&D and manufacturing capabilities, proprietary technology platforms, and proven commercialization capabilities, and led by an experienced management team, the company provides medical devices for the treatment and management of neurological and peripheral vascular diseases to doctors and patients in China and overseas. The company's current treatment areas include acute ischemic stroke (AIS), intracranial aneurysms, carotid artery stenosis, peripheral arterial and venous diseases, and dialysis-related diseases.</p><p>According to Frost & Sullivan, the company has 22 approved products and product candidates. Among domestic players in China, the company has the most comprehensive portfolio of peripheral vascular interventional products, covering a full range of arterial and venous products such as stents, balloons, catheters and filters. In addition, the company's product portfolio also includes two vascular closure device candidates, making the company the first medical device company in China to develop a vascular closure device candidate. Since its establishment in 2012, the company has systematically and comprehensively developed 45 products and product candidate portfolios, covering the neurological and peripheral vascular device market and the vascular closure device market, all of which are characterized by serious insufficient penetration and rapid development. The company's two core products are the Jiaolong intracranial thrombectomy stent and the UltrafreeTM drug-eluting PTA balloon dilatation catheter (Ultrafree DCB). These two core products have been commercialized in China, and the company is conducting further research and development on these two core products.</p><p>Financial data shows that in 2019 and 2020, the company achieved revenue of RMB 4.917 million and RMB 27.631 million, respectively; The net losses were approximately RMB 66.647 million and RMB 100 million, respectively. The majority of the operating losses were attributable to costs incurred by the Company in selling and distribution expenses, research and development expenses and administrative expenses related to going concern.</p><p><img src=\"https://static.tigerbbs.com/7ae57878256177f384fa6f1f7336dc10\" tg-width=\"667\" tg-height=\"810\" referrerpolicy=\"no-referrer\"></p><p>In addition, the company will continue to incur huge losses in 2021 as it continues to invest heavily in research and development activities to expand the development of its product candidates and seek regulatory approval for them.</p><p>The announcement stated that the company has entered into cornerstone investment agreements with 12 cornerstone investors, who have agreed, subject to certain conditions, to subscribe for a certain number of offer shares at the offer price, which can be purchased for a total amount of US$145 million.</p><p>To the best of the Company's knowledge, except that AIHC, Cormorant, Hudson Bay, Lake Bleu Prime and Octagon are all existing shareholders of the Company or their close associates, each of the Cornerstone Investors is an independent third party and is not a related party of the Company. Among them, Gaoling Fund, LP, YHG Investment, LP, and Fidelity International Lake Bleu Prime, Boyu Capital Opportunity Master Fund, AIHC Master Fund, Hudson Bay and Snow Lake Fund The subscription amounts were $30 million, $20 million, $20 million, $16 million, $16 million, $10 million, and $10 million, respectively.</p><p><img src=\"https://static.tigerbbs.com/9817ed27c529206fe64fd47ee9d9ddd2\" tg-width=\"610\" tg-height=\"726\" referrerpolicy=\"no-referrer\"></p><p>Assuming the Over-allotment Option is not exercised and the Offer Price is HK$41.25 per Share, the net proceeds from the Global Offering will be approximately HK$2.314 billion. Approximately 12.5% will be allocated to the continued research, development, production, and commercialization of the Jiaolong intracranial thrombectomy stent; Approximately 24.5% will be allocated to the continued research, development, production, and commercialization of the core product, Ultrafree DCB; Approximately 11.0% will be allocated to the continued research and development, production, and commercialization of the other five major products; Approximately 40.0% will be allocated to the other 38 products and pipelines under development to develop a product portfolio to provide full-line solutions. Approximately 3.0% will be allocated to further upgrading research and development facilities; Approximately 4.0% is allocated for potential strategic acquisitions, investments, licensed introductions, or cooperation; and approximately 5.0% will be used for working capital and general corporate purposes.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18","relate_stocks":{"02190":"归创通桥"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1175917752","content_text":"6月22日讯，归创通桥-B港交所公告，公司于2021年6月22日-25日招股，拟全球发售6000万股H股，香港公开发售占10%，国际发售占90%，另有15%超额配股权。每股39.8-42.7港元，每手500股，摩根士丹利及中信证券为联席保荐人，预期股份将于2021年7月5日于联交所主板挂牌上市。\nTiger Trade将于11:30开放申购【申购入口】\n\n申购阶梯：\n每手500股，入场费21565.15港元。\n乙组门槛为20万股，申购所需资金约8626057.58港元。\n\n就公司全面的产品组合而言，公司是中国神经和外周血管介入医疗器械市场的领导者。作为一家以自主研发及制造能力、专有技术平台及经良好往绩记录证实的商业化能力为支撑，并由经验丰富的管理团队带领的综合医疗器械公司，公司为中国及海外的医生和患者提供治疗及应对神经和外周血管疾病的医疗器械。公司目前的治疗领域包括急性缺血性脑卒中(AIS)、颅内动脉瘤、颈动脉狭窄、外周动脉和静脉疾病及透析相关疾病。\n根据弗若斯特沙利文的资料，公司拥有22款获批产品及候选产品，在中国的国内参与者中，公司拥有最全面的外周血管介入产品组合，涵盖支架、球囊、导管和滤器等全系列动脉和静脉产品。此外，公司的产品组合亦包括两款血管闭合装置候选产品，使公司成为国内首家开发出血管闭合装置候选产品的医疗器械公司。自2012年创立以来，公司已系统、全面地开发出45款产品及候选产品组合，涵盖神经及外周血管器械市场及血管闭合装置市场，这些市场都存在渗透率严重不足且发展迅速的特点。公司的两款核心产品是蛟龙颅内取栓支架和UltrafreeTM药物洗脱PTA球囊扩张导管(Ultrafree DCB)，这两款核心产品已在中国实现商业化，且公司正在对这两款核心产品展开进一步研发。\n财务资料显示，于2019年及2020年，实现收入分别为人民币491.7万元及2763.1万元;净亏损分别为约人民币6664.7万元及1亿元。经营亏损的绝大部分是由公司的销售及分销开支、研发开支以及与持续经营相关的行政开支所产生的成本所致。\n\n此外，将于2021年继续产生巨额亏损，原因是公司继续大力投资研发活动，以扩大对候选产品的开发及寻求候选产品的监管批准。\n公告称，公司已与12位基石投资者订立基石投资协议，基石投资者已同意在若干条件的规限下，按发售价认购以总金额1.45亿美元可购买的一定数目的发售股份。\n据公司所深知，除AIHC、Cormorant、Hudson Bay、Lake Bleu Prime及 Octagon均为公司现有股东或彼等的紧密联系人外，各基石投资者均为独立第三方且并非公司的关联人士。其中，Gaoling Fund, L.P.及 YHG Investment, L.P、富达国际、Lake Bleu Prime、Boyu Capital Opportunity Master Fund、AIHC Master Fund 、Hudson Bay及Snow Lake Fund认购额分别为3000万美元、2000万美元、2000万美元、1600万美元、1600万美元、1000万美元及1000万美元。\n\n假设超额配售权未获行使且假设发售价为每股股份41.25港元，全球发售净筹约23.14亿港元。约12.5%将被分配予蛟龙颅内取栓支架的持续研发、生产及商业化;约24.5%将被分配予核心产品Ultrafree DCB的持续研发、生产及商业化; 约11.0%将被分配予其他5款主要产品的持续研发、生产及商业化;约40.0%将被分配予其他38款产品及在研管线，以便开发产品组合以提供全线解决方案。约3.0%将分配予进一步升级研发设施;约4.0%被分配用于潜在战略收购、投资、授权引进或合作;及约5.0%将用于营运资金及一般公司用途。","news_type":1,"symbols_score_info":{"02190":0.9}},"isVote":1,"tweetType":1,"viewCount":4143,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
